As of 2025-09-16, the EV/EBITDA ratio of Turning Point Therapeutics Inc (TPTX) is -10.23. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. TPTX's latest enterprise value is 3,484.99 mil USD. TPTX's TTM EBITDA according to its financial statements is -340.81 mil USD. Dividing these 2 quantities gives us the above TPTX EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 11.2x - 14.3x | 12.8x |
| Forward P/E multiples | 13.9x - 31.1x | 17.1x |
| Fair Price | (89.27) - (92.01) | (96.92) |
| Upside | -217.4% - -221.1% | -227.5% |
| Date | EV/EBITDA |